FDA Approves AstraZeneca COPD Medicine

GSK’s Five-in-One Meningococcal Vaccine Under Review by the FDA

Importing drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.

FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis

With a final decision expected next February, MenABCWY combines the protective elements of GSK’s existing vaccines to target the five primary serogroups of Neisseria meningitidis.

FDA Approves New Administration Methods for SK Life Science’s Xcorpi for Adults with Partial-Onset Seizures

Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.

FDA Approves AstraZeneca’s Fasenra as Add-On Maintenance Therapy for Children Aged 6 to 11 with Severe Asthma

New methods allow the antiseizure treatment to be crushed and mixed with water for oral suspension or for use through a nasogastric tube.

Philips Respironics Finalizes Consent Decree Regarding Business Operations in the US with Department of Justice, FDA

Treatment was initially approved in 2017 for the same indication in children aged 12 and up.

April 10th 2024

The Real Cost of State Drug Importation Programs? Patient Safety

Decree comes amid the FDA’s 2021 inspection of Philips’ Murrysville facility and the subsequent voluntary recall of its sleep and respiratory care devices.

Related Content

April 18th 2024

GSK’s Five-in-One Meningococcal Vaccine Under Review by the FDA

Importing drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.

FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis

With a final decision expected next February, MenABCWY combines the protective elements of GSK’s existing vaccines to target the five primary serogroups of Neisseria meningitidis.

FDA Approves New Administration Methods for SK Life Science’s Xcorpi for Adults with Partial-Onset Seizures

FDA Approves AstraZeneca’s Fasenra as Add-On Maintenance Therapy for Children Aged 6 to 11 with Severe Asthma

New methods allow the antiseizure treatment to be crushed and mixed with water for oral suspension or for use through a nasogastric tube.

Philips Respironics Finalizes Consent Decree Regarding Business Operations in the US with Department of Justice, FDA

Treatment was initially approved in 2017 for the same indication in children aged 12 and up.

April 10th 2024